Increased myofilament Ca 2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice

Journal of Molecular and Cellular Cardiology

Volumn 52, Issue 6, 2012, Pages 1299-1307

  Fraysse, Bodvaël ^a,b   Weinberger, Florian ^c   Bardswell, Sonya C ^d   Cuello, Friederike ^d   Vignier, Nicolas ^a,b   Geertz, Birgit ^c   Starbatty, Jutta ^c   Krämer, Elisabeth ^c   Coirault, Catherine ^a,b   Eschenhagen, Thomas ^c   Kentish, Jonathan C ^d   Avkiran, Metin ^d   Carrier, Lucie ^a,b,c  

^a Sorbonne Université   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Ca 2+ sensitivity; Ca 2+ transient; Diastolic dysfunction; Hypertrophy; Mouse model

Indexed keywords

CALCIUM ION; MYOSIN BINDING PROTEIN C; CALCIUM; CARRIER PROTEIN; MYOSIN-BINDING PROTEIN C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; ECHOCARDIOGRAPHY; GENE; GENE MUTATION; GENETIC ASSOCIATION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HETEROZYGOSITY; HOMOZYGOSITY; HYPERTROPHIC CARDIOMYOPATHY; MOUSE; MYOFILAMENT; MYPBC3 GENE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SARCOMERE LENGTH; SENSITIZATION; SYSTOLIC DYSFUNCTION; TISSUE DOPPLER IMAGING; WILD TYPE; ANIMAL; DIASTOLE; GENE ORDER; GENE TARGETING; GENETICS; HEART VENTRICLE; HETEROZYGOTE; METABOLISM; MUSCLE FIBRIL; MUTATION; PATHOPHYSIOLOGY; TRANSGENIC MOUSE;

MUS;

ANIMALS; CALCIUM; CARDIOMYOPATHY, HYPERTROPHIC; CARRIER PROTEINS; DIASTOLE; ECHOCARDIOGRAPHY; GENE KNOCK-IN TECHNIQUES; GENE ORDER; HEART VENTRICLES; HETEROZYGOTE; MICE; MICE, TRANSGENIC; MUTATION; MYOCYTES, CARDIAC; MYOFIBRILS;

EID: 84860522221     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2012.03.009     Document Type: Article

References (50)

1. Maron B.J., Gardin J.M., Flack J.M., Gidding S.S., Kurosaki T.T., Bild D.E. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA study. Circulation 1995, 92:785-789.
2. Gersh B.J., Maron B.J., Bonow R.O., Dearani J.A., Fifer M.A., Link M.S., et al. ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011, 58. e261-60.
3. Elliott P., Andersson B., Arbustini E., Bilinska Z., Cecchi F., Charron P., et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008, 29:270-276.
4. Watkins H., Ashrafian H., Redwood C. Inherited cardiomyopathies. N Engl J Med 2011, 364:1643-1656.
5. Seidman C.E., Seidman J.G. Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: a personal history. Circ Res 2011, 108:743-750.
6. Carrier L., Schlossarek S., Willis M.S., Eschenhagen T. The ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy. Cardiovasc Res 2010, 85:330-338.
7. Friedrich F.W., Carrier L. Genetics of hypertrophic and dilated cardiomyopathy. Curr Pharm Biotechnol Jan 20 2012, [Epub ahead of print].
8. Harris S.P., Lyons R.G., Bezold K.L. In the thick of it: HCM-causing mutations in myosin binding proteins of the thick filament. Circ Res 2011, 108:751-764.
9. Schlossarek S., Mearini G., Carrier L. Cardiac myosin-binding protein C in hypertrophic cardiomyopathy: mechanisms and therapeutic opportunities. J Mol Cell Cardiol 2011, 50:613-620.
10. Carrier L. Cardiac myosin-binding protein C in the heart. Arch Mal Coeur Vaiss 2007, 100:238-243.
11. Barefield D., Sadayappan S. Phosphorylation and function of cardiac myosin binding protein-C in health and disease. J Mol Cell Cardiol 2010, 48:866-875.
12. El-Armouche A., Pohlmann L., Schlossarek S., Starbatty J., Yeh Y.H., Nattel S., et al. Decreased phosphorylation levels of cardiac myosin-binding protein-C in human and experimental heart failure. J Mol Cell Cardiol 2007, 43:223-229.
13. van Dijk S.J., Dooijes D., Dos Remedios C., Michels M., Lamers J.M., Winegrad S., et al. Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy. haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation 2009, 119:1473-1483.
14. van Dijk S.J., Paalberends E.R., Najafi A., Michels M., Sadayappan S., Carrier L., et al. Contractile dysfunction irrespective of the mutant protein in human hypertrophic cardiomyopathy with normal systolic function. Circ Heart Fail 2012, 5:36-46.
15. Vignier N., Schlossarek S., Fraysse B., Mearini G., Kramer E., Pointu H., et al. Nonsense-mediated mRNA decay and ubiquitin-proteasome system regulate cardiac myosin-binding protein C mutant levels in cardiomyopathic mice. Circ Res 2009, 105:239-248.
16. Richard P., Charron P., Carrier L., Ledeuil C., Cheav T., Pichereau C., et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations and implications for molecular diagnosis strategy. Circulation 2003, 107:2227-2232.
17. Olivotto I., Girolami F., Ackerman M.J., Nistri S., Bos J.M., Zachara E., et al. Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clin Proc 2008, 83:630-638.
18. Schlossarek S., Englmann D.R., Sultan K.R., Sauer M., Eschenhagen T., Carrier L. Defective proteolytic systems in Mybpc3-targeted mice with cardiac hypertrophy. Basic Res Cardiol 2012, 107:1-13.
19. Schlossarek S., Schuermann F., Geertz B., Mearini G., Eschenhagen T., Carrier L. Adrenergic stress reveals septal hypertrophy and proteasome impairment in heterozygous Mybpc3-targeted knock-in mice. J Muscle Res Cell Motil Nov 11 2011, [Epub ahead of print].
20. McConnell B.K., Fatkin D., Semsarian C., Jones K.A., Georgakopoulos D., Maguire C.T., et al. Comparison of two murine models of familial hypertrophic cardiomyopathy. Circ Res 2001, 88:383-389.
21. Harris S.P., Bartley C.R., Hacker T.A., McDonald K.S., Douglas P.S., Greaser M.L., et al. Hypertrophic cardiomyopathy in cardiac myosin binding protein-C knockout mice. Circ Res 2002, 90:594-601.
22. Carrier L., Knoell R., Vignier N., Keller D.I., Bausero P., Prudhon B., et al. Asymmetric septal hypertrophy in heterozygous cMyBP-C null mice. Cardiovasc Res 2004, 63:293-304.
23. Geisterfer-Lowrance A.A., Christe M., Conner D.A., Ingwall J.S., Schoen F.J., Seidman C.E., et al. A mouse model of familial hypertrophic cardiomyopathy. Science 1996, 272:731-734.
24. Charron P., Carrier L., Dubourg O., Tesson F., Desnos M., Richard P., et al. Penetrance of familial hypertrophic cardiomyopathy. Genet Couns 1997, 8:107-114.
25. Charron P., Dubourg O., Desnos M., Isnard R., Hagege A., Bonne G., et al. Genotype-phenotype correlations in familial hypertrophic cardiomyopathy. A comparison between mutations in the cardiac protein-C and the beta-myosin heavy chain genes. Eur Heart J 1998, 19:139-145.
26. Niimura H., Bachinski L.L., Sangwatanaroj S., Watkins H., Chudley A.E., McKenna W., et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med 1998, 338:1248-1257.
27. Bardswell S.C., Cuello F., Rowland A.J., Sadayappan S., Robbins J., Gautel M., et al. Distinct sarcomeric substrates are responsible for protein kinase D-mediated regulation of cardiac myofilament Ca2+ sensitivity and cross-bridge cycling. J Biol Chem 2010, 285:5674-5682.
28. Pohlmann L., Kroger I., Vignier N., Schlossarek S., Kramer E., Coirault C., et al. Cardiac myosin-binding protein C is required for complete relaxation in intact myocytes. Circ Res 2007, 101:928-938.
29. Loughrey C.M., Seidler T., Miller S.L., Prestle J., MacEachern K.E., Reynolds D.F., et al. Over-expression of FK506-binding protein FKBP12.6 alters excitation-contraction coupling in adult rabbit cardiomyocytes. J Physiol 2004, 556:919-934.
30. Schumacher A., Khojeini E., Larson D. ECHO parameters of diastolic dysfunction. Perfusion 2008, 23:291-296.
31. Mearini G., Gedicke C., Schlossarek S., Witt C.C., Kramer E., Cao P., et al. Atrogin-1 and MuRF1 regulate cardiac MyBP-C levels via different mechanisms. Cardiovasc Res 2010, 85:357-366.
32. Haworth R.S., Cuello F., Herron T.J., Franzen G., Kentish J.C., Gautel M., et al. Protein kinase D is a novel mediator of cardiac troponin I phosphorylation and regulates myofilament function. Circ Res 2004, 95:1091-1099.
33. Endoh M. Force-frequency relationship in intact mammalian ventricular myocardium: physiological and pathophysiological relevance. Eur J Pharmacol 2004, 500:73-86.
34. Ostap E.M. 2,3-Butanedione monoxime (BDM) as a myosin inhibitor. J Muscle Res Cell Motil 2002, 23:305-308.
35. Cazorla O., Szilagyi S., Vignier N., Salazar G., Kramer E., Vassort G., et al. Length and protein kinase A modulations of myocytes in cardiac myosin binding protein C-deficient mice. Cardiovasc Res 2006, 69:370-380.
36. Wolska B.M., Solaro R.J. Method for isolation of adult mouse cardiac myocytes for studies of contraction and microfluorimetry. Am J Physiol 1996, 271:1250-1255.
37. Spurgeon H.A., duBell W.H., Stern M.D., Sollott S.J., Ziman B.D., Silverman H.S., et al. Cytosolic calcium and myofilaments in single rat cardiac myocytes achieve a dynamic equilibrium during twitch relaxation. J Physiol 1992, 447:83-102.
38. Colson B.A., Bekyarova T., Fitzsimons D.P., Irving T.C., Moss R.L. Radial displacement of myosin cross-bridges in mouse myocardium due to ablation of myosin binding protein-C. J Mol Biol 2007, 367:36-41.
39. Beuckelmann D.J., Erdmann E. Ca(2+)-currents and intracellular [Ca2+]i-transients in single ventricular myocytes isolated from terminally failing human myocardium. Basic Res Cardiol 1992, 87(Suppl. 1):235-243.
40. Studer R., Reinecke H., Bilger J., Eschenhagen T., Bohm M., Hasenfuss G., et al. Gene expression of the cardiac Na(+)-Ca2+ exchanger in end-stage human heart failure. Circ Res 1994, 75:443-453.
41. Pieske B., Maier L.S., Piacentino V., Weisser J., Hasenfuss G., Houser S. Rate dependence of [Na+]i and contractility in nonfailing and failing human myocardium. Circulation 2002, 106:447-453.
42. Mulieri L.A., Hasenfuss G., Leavitt B., Allen P.D., Alpert N.R. Altered myocardial force-frequency relation in human heart failure. Circulation 1992, 85:1743-1750.
43. Michels M., Soliman O.I., Kofflard M.J., Hoedemaekers Y.M., Dooijes D., Majoor-Krakauer D., et al. Diastolic abnormalities as the first feature of hypertrophic cardiomyopathy in Dutch myosin-binding protein C founder mutations. JACC Cardiovasc Imaging 2009, 2:58-64.
44. Ho C.Y., Carlsen C., Thune J.J., Havndrup O., Bundgaard H., Farrohi F., et al. Echocardiographic strain imaging to assess early and late consequences of sarcomere mutations in hypertrophic cardiomyopathy. Circ Cardiovasc Genet 2009, 2:314-321.
45. Georgakopoulos D., Christie M.E., Giewat M., Seidman C.M., Seidman J.G., Kass D.A. The pathogenesis of familial hypertrophic cardiomyopathy: early and elvolving effects from an a-cardaic myosin heavy chain missense mutation. Nat Med 1999, 5:327-330.
46. Borlaug B.A., Kass D.A. Mechanisms of diastolic dysfunction in heart failure. Trends Cardiovasc Med 2006, 16:273-279.
47. Borbely A., Falcao-Pires I., van Heerebeek L., Hamdani N., Edes I., Gavina C., et al. Hypophosphorylation of the Stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium. Circ Res 2009, 104:780-786.
48. Kruger M., Kotter S., Grutzner A., Lang P., Andresen C., Redfield M.M., et al. Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. Circ Res 2009, 104:87-94.
49. Hudson B., Hidalgo C., Saripalli C., Granzier H. Hyperphosphorylation of mouse cardiac titin contributes to transverse aortic constriction-induced diastolic dysfunction. Circ Res 2011, 8:858-866.
50. Lovelock J.D., Monasky M.M., Jeong E.M., Lardin H.A., Liu H., et al. Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circ Res 2012, 110:841-850.